Funding opportunities
Open and upcoming programs from Canadian funders and US federal grants (Grants.gov). Deadlines first, then rolling intakes.
US Travelers Health Research, Surveillance, Communication, and Outreach Network
Centers for Disease Control and Prevention - ERA · Deadline 2026-11-05
The NOFO supports CDC"s efforts to protect U.S. residents traveling internationally. The goal is to help U.S. travelers with pre-travel preparation, access to timely health information while traveling, and timely research on health conditions.The project will:Improve access to high quality travel preparation information for both healthcare providers and travelers.Collect health information before, during, and after travel through innovative electronic medical record (EMR), web, and mobile phone applications.Build on this platform to conduct timely research on emerging health threats.This NOFO will also increase the awareness of travel medicine among primary care providers and provide them with appropriate tools in advising international travelers with up-to-date recommendations. Awards range from $750,000 to $1,000,000.
Request for Information - Gauging Investor Interest in the Development and Commercialization of Subsurface Energy Technologies
National Energy Technology Laboratory · Deadline 2026-11-05
The U.S. Department of Energy (DOE)’s Hydrocarbons and Geothermal Energy Office (HGEO) is issuing this Request for Information (RFI) to notify parties of its potential interest in connecting private capital/ public-private partnership programs to industry opportunities. This initiative provides HGEO’s technical expertise across the Office of Subsurface Energy’s three core program areas: Coal, Oil & Gas, and Geothermal. Ultimately, the goal is to use HGEO’s research and development (R&D) capabilities to support industry and capital.Through this RFI, DOE requests input from all stakeholders, particularly the financial sector, to gauge investor interest in the development and commercialization of subsurface-energy technologies. This is solely a request for information and not a Notice of Funding Opportunity (NOFO). DOE’s HGEO is not accepting applications for funding at this time. Awards range from $1 to $2.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2026-11-06
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. Awards up to $350,000.
Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health · Deadline 2026-11-06
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
Functional Target Validation for Alzheimer's Disease-Related Dementias
National Institutes of Health · Deadline not published
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies. NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess the
DoW Parkinson’s, Early Investigator Research Award
Defense Health Agency Contracting Activity - DHACA · Deadline 2026-11-06
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience. · Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to t
DoW Parkinson’s, Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA · Deadline 2026-11-06
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs. · Preliminary data are required. · Clinical trials are allowed.
ROSES25: A.15 Biosphere
NASA Headquarters · Deadline 2026-11-06
The close date above is the date for the Step-2 proposal due date. The Step-1 proposal due date is September 4, 2026 . Step-2 proposals cannot be submitted if a Step-1 proposal was not submitted. NOTICE: October 8, 2026. A requirement to budget for travel to an annual PI meeting to the furthest coast has been added to Section 4.2.1. New text is in bold. NOTICE: September 18, 2026. Details on the redacted and anonymized budget requirements have been added to Table A.15-1 to make it consistent with Section 4.2.1, and the instructions regarding BioSketches and Current and Pending Support in Table A.15-2 have been improved. New text is in bold and deleted text is struck through NOTICE: August 4, 2026. Going forward, a $0.09/SBU charge now applies to all proposing to Earth Science (ROSES Appendix A) to use any NASA high-end computing resource. Proposers must account for this in their budget, per the instructions provided in Section 7.3 of ROSES-25 A.1 Earth Science Research Overview . NOTICE: Amended July 20, 2026. This amendment adds this new program element to ROSES-2025. This element uses a two-step proposal process (Section 4). Step-1 proposals are due by September 4, 2026, and St
Fiscal Year 2027 Defense University Research Instrumentation Program (DURIP)
Air Force Office of Scientific Research · Deadline 2026-11-06
The Department of Defense (DoD) announces the Fiscal Year 2027 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. Awards range from $50,000 to $7,000,000.
Fiscal Year (FY) 2027 Department of War (DoW) Defense University Research Instrumentation Program (DURIP)
Office of Naval Research · Deadline 2026-11-06
In accordance with EO 14332, Improving Oversight of Federal Grantmaking, dated 7 August 2025, and EO 14303, Restoring Gold Standard Science, dated 23 May 2025, this Announcement seeks proposals from universities to purchase equipment and instrumentation in support of research in areas of interest to the DoW, reflecting the basic research priorities for the Department of War and advancing the administration and agency priorities (c.f., OMB memo M-25-34 “Fiscal Year 2027 Administration Research and Development Budget Priorities and Cross-Cutting Actions”). DoW interests include the areas of research supported by the Army Research Office (ARO), the Office of Naval Research (ONR), and the Air Force Office of Scientific Research (AFOSR). A central purpose of the DURIP is to provide equipment and instrumentation to enhance research related education in areas of interest and priority to the DoW. Therefore, your proposal must address the impact of the equipment or instrumentation on your institution’s ability to educate students through research in disciplines important to DoW missions. Awards range from $50,000 to $3,000,000.
Fiscal Year (FY) 2027 Department of War (DoW) Defense University Research Instrumentation Program (DURIP)
Dept of the Army -- Materiel Command · Deadline 2026-11-06
Department of Army: The Department of War (DoW) announces the Fiscal Year 2027 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. Awards range from $50,000 to $3,000,000.
BJA FY 2026 Tribal Civil and Criminal Legal Assistance
Bureau of Justice Assistance · Deadline 2026-11-06
This is a notice of funding opportunity (NOFO) for the BJA FY 2026 Tribal Civil and Criminal Legal Assistance Program. This opportunity will support legal assistance to eligible tribal members, federally recognized Indian tribes, and tribal justice systems that provide legal aid and indigent defense services to tribal communities located in rural and remote regions throughout the United States where legal services are sparse. This NOFO will also support specialized training and technical assistance (TTA) to grantees for the development, enrichment, and enhancement of tribal courts and justice system operations. This includes tribal and state joint jurisdiction; veterans’ clinics and legal assistance for Native American veterans; Missing Murdered and Indigenous People; Violence Against Women Act; Tribal Law and Order Act; and Special Tribal Criminal Jurisdiction. Awards up to $600,000.
Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
National Institutes of Health · Deadline 2026-11-09
Applications for a 3-year extension/renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) clinical trial consortium are requested to fully meet the enrollment targets, complete participant follow-up, and finalize data analysis and dissemination of study findings. This Notice of Funding Opportunity (NOFO) invites a Single Source application for the eligible organization, the Scientific and Data Research Center (SDRC) already involved in the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2026-11-09
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from the eligible organization to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, applications will be peer-reviewed, and only meritorious applications will be considered for funding. Through this NOFO, the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites an application to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement that addresses specific knowledge gaps in the development and progression of type 1 diabetes complications. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples.
Fiscal Year (FY) 2026 Funding Opportunity for Indian Tribes and Intertribal Consortia for Nonpoint Source Management Grants Under Clean Water Act Section 319
Environmental Protection Agency · Deadline 2026-11-09
The purpose of this Notice of Funding Opportunity (NOFO) is to support eligible Tribes and intertribal consortia to implement approved Nonpoint Source (NPS) management programs developed pursuant to CWA Section 319(b)(1). The Clean Water Act (CWA) Section 319(h) authorizes the EPA to award grants to eligible Tribes and intertribal consortia to implement approved NPS management programs. This NOFO will fund implementation of best management practices (BMPs) and measures that have been outlined in Tribal NPS Management Program Plans to address NPS pollution sources that have been identified in a Tribe’s Assessment Report. Eligible applicants to this Notice of Funding Opportunity (NOFO) are federally recognized Tribes and intertribal consortia that meet the eligibility requirements described in Section 2.A. Awards up to $175,000.
Balanced Prosecution of Transnational Organized Crime Cases
Bureau of International Narcotics-Law Enforcement · Deadline 2026-11-09
The Bureau of International Narcotics and Law Enforcement Affairs (INL) of the U.S. Department of State announce an open competition for organizations to submit applications to carry out a project to develop a software-based weighted, random case-allocation system to prevent selective prosecution of transnational organized crime and money laundering cases. Political interference in the prosecution service remains a barrier to fighting transnational organized crime and achieving other U.S. objectives in Serbia. As requested by the High Prosecutorial Council, the body responsible for oversight of the prosecution service, this grant will reduce political manipulation of prosecutions and improve outcomes in extradition cases and cases involving high-level corruption and transnational criminal organization (TCO) leaders whose activities harm U.S. national security interests through random allocation of cases Awards range from $750,000 to $1,100,000.
Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2026-11-10
This Notice of Funding Opportunity (NOFO) invites applications proposing a Data Coordinating Center that integrates and disseminates multiscale mouse brain datasets for the aging and Alzheimer's disease (AD) research community. The Data Coordinating Center will establish the Aging and AD Mouse Brain Atlas (AD-MBA), which will serve as a central, unified research resource for multi-omic and connectomic mouse brain datasets emerging from the NIA AD Multimodal Atlas Projects (AD-MAPs). The Data Coordinating Center will (1) leverage the NIA-supported AD Knowledge Portal data infrastructure to facilitate hosting, deposition, and dissemination of multimodal datasets generated by the AD-MAPs program, (2) facilitate collaborative analyses among the data-contributing teams, (3) develop/optimize and incorporate tools for multiscale integration of multi-omics and connectomics datasets, and (4) create a broadly accessible web-based interface for the visualization and dissemination of integrated multiscale data.
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health · Deadline 2026-11-10
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2026-11-10
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies Awards up to $300,000.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2026-11-10
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Awards up to $150,000.